Intelligent Bio Solutions (INBS)
Market Price (12/29/2025): $4.84 | Market Cap: $4.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
Intelligent Bio Solutions (INBS)
Market Price (12/29/2025): $4.84Market Cap: $4.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68% | Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -181% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -317% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Non-Invasive Drug Screening. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -308%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -317% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -267% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 111% | ||
| Key risksINBS key risks include [1] severe financial distress and operational inefficiencies, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Non-Invasive Drug Screening. |
| Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -181% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -317% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -308%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -317% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -267% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 111% |
| Key risksINBS key risks include [1] severe financial distress and operational inefficiencies, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Reverse Stock Split. Intelligent Bio Solutions Inc. announced a 1-for-10 reverse stock split, effective December 15, 2025. While a reverse split mechanically increases the per-share price, such actions are often perceived negatively by the market, signaling underlying issues like the company struggling to maintain its stock price above exchange minimums.
2. Negative Analyst Sentiment and Financial Performance Concerns. An investor update in December 2025 was accompanied by an "Underperform" rating from TipRanks' AI Analyst, citing "poor financial performance, with consistent losses and negative cash flows." Additionally, valuation metrics were deemed "unfavorable" due to a negative P/E ratio and no dividend yield, alongside a "Sell" rating and a low price target of $0.50.
Show more
Stock Movement Drivers
Fundamental Drivers
The -56.8% change in INBS stock from 9/28/2025 to 12/28/2025 was primarily driven by a -51.1% change in the company's P/S Multiple.| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 11.20 | 4.84 | -56.79% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3.05 | 3.29 | 7.85% |
| P/S Multiple | 2.57 | 1.26 | -51.07% |
| Shares Outstanding (Mil) | 0.70 | 0.85 | -22.11% |
| Cumulative Contribution | -58.90% |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| INBS | -56.8% | |
| Market (SPY) | 4.3% | 29.7% |
| Sector (XLV) | 15.2% | 3.5% |
Fundamental Drivers
The -68.4% change in INBS stock from 6/29/2025 to 12/28/2025 was primarily driven by a -58.2% change in the company's P/S Multiple.| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 15.30 | 4.84 | -68.37% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2.94 | 3.29 | 12.11% |
| P/S Multiple | 3.01 | 1.26 | -58.22% |
| Shares Outstanding (Mil) | 0.58 | 0.85 | -48.08% |
| Cumulative Contribution | -75.68% |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| INBS | -68.4% | |
| Market (SPY) | 12.6% | 21.5% |
| Sector (XLV) | 17.0% | -0.4% |
Fundamental Drivers
The -66.2% change in INBS stock from 12/28/2024 to 12/28/2025 was primarily driven by a -124.3% change in the company's Shares Outstanding (Mil).| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 14.30 | 4.84 | -66.15% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3.19 | 3.29 | 3.26% |
| P/S Multiple | 1.71 | 1.26 | -26.49% |
| Shares Outstanding (Mil) | 0.38 | 0.85 | -124.26% |
| Cumulative Contribution | -118.42% |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| INBS | -66.2% | |
| Market (SPY) | 17.0% | 22.6% |
| Sector (XLV) | 13.8% | 5.4% |
Fundamental Drivers
The -99.0% change in INBS stock from 12/29/2022 to 12/28/2025 was primarily driven by a -13676.5% change in the company's Shares Outstanding (Mil).| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 480.24 | 4.84 | -98.99% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 3.29 | ∞% |
| P/S Multiple | ∞ | 1.26 | -100.00% |
| Shares Outstanding (Mil) | 0.01 | 0.85 | -13676.48% |
| Cumulative Contribution | � |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| INBS | -88.1% | |
| Market (SPY) | 48.4% | 15.2% |
| Sector (XLV) | 17.8% | 3.7% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| INBS Return | -33% | -81% | -86% | -92% | -65% | -64% | -100% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| INBS Win Rate | 0% | 17% | 33% | 33% | 33% | 42% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| INBS Max Drawdown | -33% | -83% | -87% | -95% | -74% | -64% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | INBS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.9% | -25.4% |
| % Gain to Breakeven | 78809.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -32.8% | -33.9% |
| % Gain to Breakeven | 48.9% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Intelligent Bio Solutions's stock fell -99.9% during the 2022 Inflation Shock from a high on 1/15/2021. A -99.9% loss requires a 78809.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 brief analogies for Intelligent Bio Solutions (INBS):
- Like a focused Abbott Laboratories for non-invasive, rapid diagnostic testing.
- An OraSure Technologies specializing in non-invasive, rapid drug screening and point-of-care diagnostics.
AI Analysis | Feedback
- INBS001: A sublingual film drug candidate being developed for the rapid treatment of anaphylaxis.
- INBS002: A sublingual film drug candidate being developed for the treatment of severe acute pain.
- INBS003: A sublingual film drug candidate being developed for the treatment of opioid use disorder.
AI Analysis | Feedback
Intelligent Bio Solutions (INBS) sells primarily to other companies and organizations rather than directly to individuals. Based on its public filings, the company has stated that it does not currently have any customers that account for more than 10% of its total revenue. Therefore, no individually named major customer companies are publicly disclosed.
However, Intelligent Bio Solutions markets and sells its products, primarily the Intelligent Fingerprint Drug Screening System and rapid diagnostic tests, to a broad range of customers within the following categories:
- Workplace: This includes various industries and corporations that require drug screening for employees and compliance.
- Criminal Justice: This category encompasses entities such as law enforcement agencies, correctional facilities, and probation services that utilize drug screening and diagnostic tools.
- Healthcare: Hospitals, clinics, and other healthcare providers using rapid diagnostic tests for conditions like sepsis and tuberculosis.
AI Analysis | Feedback
- Avioq, Inc.
- Thermo Fisher Scientific Inc. (NYSE: TMO)
- Acu-Tech Scientific, LLC
- DCN Diagnostics, Inc.
AI Analysis | Feedback
Harry Simeonidis President & CEO
Mr. Simeonidis has more than 25 years of experience in healthcare, pharmaceutical, and life sciences, holding various senior management positions across Asia Pacific. Before joining Intelligent Bio Solutions, he served as the General Manager, Surgery, Asia Pacific, at GE Healthcare, where he led significant market expansion. Prior to that, he was the President and CEO of GE Healthcare ANZ for nine years.
Spiro Sakiris Chief Financial Officer
Mr. Sakiris is a seasoned finance professional with over 35 years of expertise in accounting, taxation, Initial Public Offerings (IPOs), capital raising, and business system designs. His experience spans International Financial Reporting Standards (IFRS) and US Generally Accepted Accounting Principles (GAAP) frameworks within the life science sector. He is a member of the Institute of Chartered Accountants of Australia & New Zealand.
Callistus Sequeira Vice President of Global Quality & Operations
Mr. Sequeira brings over 20 years of experience in manufacturing, operations, and procurement. He holds a Bachelor of Engineering, a Master of Arts in International Business, and a postgraduate qualification from the Chartered Institute of Marketing. He is also a Lean Six Sigma Black Belt.
Doug Heath Vice President of Global Sales
Mr. Heath is a senior sales professional with over a decade of experience leading commercial strategies across global markets. Earlier in his career, he contributed to several large-scale infrastructure projects in the Middle East, including the Burj Khalifa and Lusail Village for the Qatari FIFA World Cup.
Anna Turkington Vice President of Marketing
Ms. Turkington is a senior marketing and communications specialist with over ten years of experience in corporate, non-profit, and marketing roles.
AI Analysis | Feedback
The key risks to Intelligent Bio Solutions (INBS) include:- Financial Health and Profitability Concerns: Intelligent Bio Solutions faces significant financial challenges, with reported negative profitability margins, including a Net Margin of -346.3% and an Operating Margin of -341.55%. The company's financial health grades indicate distress, with a low Altman Z-Score and a Piotroski F-Score of 3. This suggests operational inefficiencies and potential liquidity issues, further highlighted by a current ratio of 0.92. These factors point to significant losses relative to revenue and an overarching risk related to the company's ability to achieve sustainable profitability and manage cash burn.
- Regulatory Challenges and FDA Approval Uncertainty: A crucial risk for INBS is the uncertainty surrounding FDA clearance for its non-invasive drug screening technology to enter the U.S. market. While the company has submitted a 510(k) application and anticipates clinical studies to conclude in the first half of 2026, with clearance later that year, FDA approval is not guaranteed. Successful FDA clearance is essential to unlock access to the multi-billion dollar U.S. workplace drug testing market, and any delays or failure to secure this approval would significantly impede the company's growth strategy and revenue potential.
- Nasdaq Listing Compliance: Intelligent Bio Solutions recently received a deficiency letter from Nasdaq due to its common stock failing to meet the minimum bid price requirement of $1.00 per share. To address this, the company has initiated a 1-for-10 reverse stock split. Failure to regain compliance with Nasdaq's listing rules by June 15, 2026, could lead to the delisting of the company's shares, which would impact investor confidence and market accessibility.
AI Analysis | Feedback
null
AI Analysis | Feedback
Intelligent Bio Solutions (INBS) operates in several significant addressable markets for its main products and services.
For its Intelligent Fingerprinting Drug Screening System and SmarTest® Sweat Drug Testing Patch, the company addresses:
- The global drug screening market, which is projected to reach approximately $14.9 billion by 2030. Another estimate indicates this market is valued at USD 8.49 billion in 2025 and is projected to reach USD 18.12 billion by 2030.
- The U.S. workplace drug testing market, which is a significant opportunity exceeding $5 billion following anticipated FDA clearance in 2025.
- The global point-of-care (POC) drug of abuse testing market, estimated at USD 1.08 billion in 2024 and projected to reach USD 2.45 billion by 2033.
- The U.S. point-of-care (POC) drug of abuse testing market, which was estimated at USD 370.55 million in 2024 and is projected to grow to USD 821.14 million by 2033. The U.S. accounted for 84% of the North American POC drug abuse testing market in 2024.
- The Latin American drug screening market, projected to reach $1.1 billion by 2030.
- The UK drug testing market, projected to hit $453 million by 2030.
In addition to these specific drug testing markets, INBS's proprietary biosensor platform and wearable patch technologies position it within broader markets:
- The global biosensors market was valued at approximately USD 27.40 billion in 2024 and is projected to grow to USD 55.78 billion by 2032. Other estimates place the global biosensors market at USD 30.04 billion in 2024, growing to USD 68.72 billion by 2034, or USD 30.0 billion in 2024, projected to reach USD 48.6 billion by 2030. North America held the largest share of the global biosensors market in 2024.
- The global wearable biosensors market was valued at USD 30.50 billion in 2024 and is expected to reach nearly USD 56.88 billion by 2032.
AI Analysis | Feedback
Intelligent Bio Solutions (INBS) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies:
-
Growth in Customer Accounts and Recurring Cartridge Sales: The company has demonstrated consistent growth in its customer base, with new accounts being a primary driver of revenue. For instance, in fiscal Q1 2026, Intelligent Bio Solutions secured 33 new customer accounts, increasing its total active accounts to 480. In Q3 2025, 35 new accounts were added, bringing the total to over 450 active accounts. A significant aspect of this growth is the increasing demand for higher-margin cartridges, which contribute to a recurring revenue model and are expected to be a main source of future revenue.
-
U.S. Market Expansion via FDA Clearance: A critical driver for Intelligent Bio Solutions is its ongoing effort to secure U.S. FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System. This clearance is essential for expanding the use of its technology beyond "Forensic Use Only" settings into the broader U.S. market, which the company identifies as the world's largest drug screening market. Achieving FDA clearance is a strategic priority for fiscal year 2026, paving the way for substantial market penetration.
-
International Expansion and Distribution Network Enhancement: Intelligent Bio Solutions is actively expanding its global commercial footprint, currently serving customers across 24 countries with 18 distribution partners. Strategic initiatives include strengthening its presence in key European markets, the Middle East, and Latin America. The launch of localized multilingual websites (Arabic, Italian, and Spanish) and the integration of these languages into its drug screening reader are designed to access markets representing over 1.4 billion people, with the Latin American drug screening market alone projected to reach $1.1 billion by 2030 and the Saudi Arabian workplace drug testing market projected to reach $64.5 million by 2030. A global distribution agreement with SMARTOX further supports international growth.
-
Launch of New Products and Expanded Offerings: Beyond its core fingerprinting system, Intelligent Bio Solutions is broadening its product portfolio. A global distribution agreement with SMARTOX introduces the "SmarTest Sweat Patch," which offers continuous drug monitoring over 7-12 days, complementing the short-window detection of the fingerprint test. This new product expands the company's addressable market to include rehabilitation and justice settings and allows for the detection of a wider range of substances. The company also envisions broader applications for its sweat-based technology in general health monitoring.
AI Analysis | Feedback
Share Issuance
- Intelligent Bio Solutions raised approximately $4.6 million through equity offerings during fiscal year 2025 (ended June 30, 2025).
- In July 2025, the company announced an agreement with warrant holders to exercise existing warrants, expected to generate approximately $3.8 million in gross proceeds.
- In September 2024, an At The Market (ATM) Offering Agreement was established, allowing for the sale of common stock with an aggregate sales price of up to $3 million.
Outbound Investments
- On October 4, 2022, Intelligent Bio Solutions acquired Intelligent Fingerprinting Limited, a company based in England and Wales.
Capital Expenditures
- Net cash used in investing activities amounted to $474,891 for the three months ended September 30, 2022.
- For the three months ended September 30, 2023, net cash used in investing activities was $0.
Trade Ideas
Select ideas related to INBS. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Intelligent Bio Solutions
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Price Behavior
| Market Price | $4.84 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/23/2020 | |
| Distance from 52W High | -81.7% | |
| 50 Days | 200 Days | |
| DMA Price | $7.64 | $13.38 |
| DMA Trend | down | down |
| Distance from DMA | -36.7% | -63.8% |
| 3M | 1YR | |
| Volatility | 93.1% | 93.6% |
| Downside Capture | 389.16 | 199.04 |
| Upside Capture | -89.56 | 61.51 |
| Correlation (SPY) | 26.0% | 22.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.88 | 2.13 | 1.82 | 1.83 | 1.14 | 1.92 |
| Up Beta | 2.34 | 1.82 | 1.53 | 1.26 | 0.73 | 1.96 |
| Down Beta | 6.22 | 3.30 | 2.81 | 2.72 | 1.19 | 0.84 |
| Up Capture | -110% | -9% | -96% | 20% | 90% | 61% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 5 | 14 | 24 | 54 | 109 | 321 |
| Down Capture | 422% | 279% | 322% | 250% | 144% | 112% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 15 | 26 | 37 | 69 | 130 | 411 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullReturns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/7/2025 | 1.8% | -6.6% | -6.1% |
| 8/7/2025 | -1.9% | -4.5% | 6.1% |
| 5/13/2025 | -5.5% | -5.9% | 39.7% |
| 2/6/2025 | 8.7% | 21.5% | 13.8% |
| 9/9/2024 | 10.1% | 25.1% | -17.3% |
| 4/18/2024 | -2.1% | -11.8% | -19.6% |
| 2/2/2024 | -38.8% | 13.7% | -9.9% |
| 11/8/2023 | 92.5% | 150.7% | 32.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 6 | 6 |
| # Negative | 9 | 10 | 10 |
| Median Positive | 6.5% | 20.1% | 20.5% |
| Median Negative | -5.5% | -7.4% | -24.4% |
| Max Positive | 92.5% | 150.7% | 39.7% |
| Max Negative | -38.8% | -38.7% | -63.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11122025 | 10-Q 9/30/2025 |
| 6302025 | 8152025 | 10-K 6/30/2025 |
| 3312025 | 5132025 | 10-Q 3/31/2025 |
| 12312024 | 2132025 | 10-Q 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 9182024 | 10-K 6/30/2024 |
| 3312024 | 5082024 | 10-Q 3/31/2024 |
| 12312023 | 2092024 | 10-Q 12/31/2023 |
| 9302023 | 11082023 | 10-Q 9/30/2023 |
| 6302023 | 8232023 | 10-K 6/30/2023 |
| 3312023 | 5112023 | 10-Q 3/31/2023 |
| 12312022 | 2142023 | 10-Q 12/31/2022 |
| 9302022 | 11142022 | 10-Q 9/30/2022 |
| 6302022 | 9222022 | 10-K 6/30/2022 |
| 3312022 | 5162022 | 10-Q 3/31/2022 |
| 12312021 | 2112022 | 10-Q 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.